Business ❯ Pharmaceutical Industry

Regulatory Affairs

FDA Approval FDA FDA Approvals Drug Approval Process Drug Approval FDA Regulations Product Oversight Market Withdrawal Taxation Compliance Strategies Clinical Trials Patent Regulations Market Regulation Market Access FDA Approval Process Product Safety European Medicines Agency Quality Assurance Health Policy Workforce Management Transparency Initiatives Compliance Issues

FDA Seeks Removal of Suicide Warnings From Saxenda, Wegovy and Zepbound

The move follows FDA analyses of 91 trials plus a 2.24 million‑patient claims study that found no increased risk.

Zenas' Obexelimab Meets Phase 3 Goals in IgG4-Related Disease With 56% Flare Risk Cut

FDA Adds Brain Tumor Warning to Two Depo‑Provera Injections

Gilead’s BIC/LEN HIV Tablet Matches Biktarvy in Phase 3 Switch Trial

Sanofi Ends PPMS Bid After Tolebrutinib Fails Phase 3 as FDA Delays Review for nrSPMS

Yale Study Finds Only 24% of Medicines Tested Reach Trial-Host Countries Within Five Years

FDA Names First 9 Drugs for ‘National Priority’ Fast-Track Reviews, Targeting 1–2-Month Decisions

Former FDA Biologics Chief Peter Marks Joins Eli Lilly to Lead Infectious Disease and Molecule Discovery

FDA to Publicly Release All Future Drug Rejection Letters, Posts 89 Recent CRLs

FDA Launches Coordinated Pathway to Review Therapies for Ultra-Rare Genetic Diseases

FDA Approves First New Fibromyalgia Treatment in 15 Years

Moderna Withdraws Flu-COVID Vaccine Application After FDA Requests More Data